Pharmacological treatment of adult ADHD

Current Opinion in Psychiatry

Volumn 25, Issue 6, 2012, Pages 529-534

  Bitter, István ^a   Angyalosi, Anna ^a   Czobor, Pál ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Adult; Attention deficit hyperactivity disorder; Nonstimulant; Pharmacotherapy; Stimulant

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; BUSPIRONE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; DOPAMINE; LISDEXAMPHETAMINE DIMESYLATE; MEMANTINE; METHYLPHENIDATE; UNCLASSIFIED DRUG; VENLAFAXINE;

ATTENTION DEFICIT DISORDER; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRIVING ABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EXECUTIVE FUNCTION; FUNCTIONAL DISEASE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; META ANALYSIS; MONOTHERAPY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOCIAL DISABILITY; SOCIAL INTERACTION; SUBSTANCE ABUSE; TREATMENT DURATION; TREATMENT RESPONSE;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84867330172     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328356f87f     Document Type: Review

References (49)

1. Fayyad J, De Graaf R, Kessler RC, et al. Cross national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007; 190:402-409. (Pubitemid 46706952)
2. Barkley RA, Fischer M, Smallich L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002; 111:279-289. (Pubitemid 34441206)
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC, USA: American Psychiatric Association Press; 1994.
4. National Institute for Health and Clinical Excellence. Attention Deficit Hyper-activity Disorder: diagnosis and management of adult ADHD in children, young people, and adults. http://www.nice.org.uk/nicemedia/live/12061/ 42107/42107.pdf. [Accessed 28 May 2012]
5. Retz W, Junginger PR, Thorme J, Rösler M. Pharmacological treatment of adult ADHD in Europe. World J Biol Psychiatry 2011; 12 (Suppl 1):89-94.
6. Duong S, Chung K, Wigal SB. Metabolic, toxicological and safety considera-tion for drugs used to treat ADHD. Expert Opin Drug Metab Toxicol 2012; 8:543-552.
7. Volkow ND, Wang GJ, Fowler JS, et al. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improve-ment in adults with attention deficit hyperactivity disorder. J Neurosci 2012; 32:841 -849.
8. Bright JM. Abuse of medications employed for the treatment of ADHD: result from a large-scale community survey. Medscape J Med 2008; 7; 10:115.
9. Hodgkins P, Sasane R, Christensen L, et al. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Curr Med Res Opin 2011; 27:53-62.
10. Hinshaw SP, Scheffler RM, Fulton BD, etal. International variation intreatment proceduresfor ADHD: social contextand recenttrends. Psychiatr Serv2011; 62:459-464.
11. Santosh PJ, Sattar S, Canagaratnam M. Efficacy and tolerability of pharma-cotherapies for attention deficit hyperactivity disorder in adults. CNS Drugs 2011; 25:737-763.
12. Wilens TE, Morrison NR, Prince J. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother 2011; 11:1443-1465.
13. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. Bupropion foradults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci 2011; 65:611 -617.
14. Amiri S, Farhang S, Ghoreishizadek MA, et al. Double-blind controlled studyof venlafaxine for treatment of adults with attention-deficit/hyperactivity disorder. Hum Psychopharmacol 2012; 27:76-81.
15. Surman CB, Hammerness PG, Petty C, et al. A pilot open label prospective study of memantine monotherapy in adults with ADHD. World J Biol Psychiatry 2012. [Epub ahead of print]
16. Adler LA, Lynch LR, Shaw DM, et al. Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. Postgrad Med 2011; 123:71 -79.
17. Marchant BK, Reimherr FW, Robison RJ, etal. Methylphenidate transdermal system in adult ADHD and impact on emotional and oppositional symptoms. JAtten Disord 2011; 15:295-304.
18. Spencer TJ, Mick E, Surman CB, et al.Arandomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord 2011; 15:286-294.
19. Ginsberg Y, Lindefors N. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. Br J Psychiatry 2012; 200:68-73.
20. Retz W, Rösler M, Ose C, etal. Multiscaleassessmentoftreatmentefficacy in adults with ADHD: a randomized, placebo-controlled, multicentre study with extended-release methylphenidate. World J Biol Psychiatry 2012; 13:48-59.
21. Wender PH, Reimherr FW, Marchant BK, et al. A one year trial of methyl-phenidate in the treatment of ADHD. J Atten Disord 2011; 15:36-45.
22. Biederman J, Fried R, Hammerness P, etal. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using avalidated driving simulator paradigm. J Psychiatr Res 2012; 46:484-491.
23. Brown TE, Brams M, Gasior M, et al. Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfeta-mine dimesylate treatment in adults. Curr Med Res Opin 2011; 27:23-33.
24. Du Paul GJ, Weyandt LL, Rossi JS, et al. Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD. J Atten Disord 2012; 16:202-220.
25. Faraone SV, Spencer TJ, Kollins SH, et al. Dose response effects of lisdex-amfetamine dimesylate treatment in adults with ADHD: an exploratory study. J Atten Disord 2011; 16:118-127.
26. Ginsberg L, Katic A, Adeyi B, et al. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit hyperactivity disorder stratified by baseline severity. Curr Med Res Opin 2011; 27:1097-1107.
27. Kollins SH, Youcha S, Lasser R, Thase ME. Lisdexamfetamine dimesylate for the treatment of attention-deficit/hyperactivity disorder in adults with a history of depression orhistoryofsubstance usedisorder. Innov Clin Neurosci 2011; 8:28-32.
28. Wigal TE, Brams M, Gasior M, et al. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel find-ings using a simulated adult workplace environment design. Behav Brain Funct 2010; 6:34.
29. Brown TE, Holdnack J, Saylor K, et al. Effect of atomoxetine on executive function impairments in adultswith ADHD. JAtten Disord 2011; 15:130-138.
30. Gabriel A, Violato C. Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study. Atten Defic Hyperact Disord 2011; 3:319-326.
31. Marchant BK, Reimherr FW, Halls C, etal. Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine. J Atten Disord 2011; 3:237-244.
32. Mc Rae-Clark AL, Carter RE, Killeen TK, et al. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with ADHD. Am J Addict 2010; 19:481 -489.
33. Sutherland SM, Adler LA, Chen C, et al. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. J Clin Psychiatry 2012; 73:445-450.
34. Takahashi M, Takita Y, Goto T, et al. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci 2011; 65:55-63.
35. Young JL, Sarkis E, Qiao M, Wietecha L. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2011; 34:51-60.
36. Mészáros A, Czobor P, Bálint S, et al. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsycho-pharmacol 2009; 12:1137-1147.
37. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010; 70:754-763.
38. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebo-con-trolled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007; 68:93-101. (Pubitemid 46220130)
39. Young SJ, Adamou M, Bolea B, et al. The identification and management of ADHD offenders within the criminal justice system: a consensus statement from the UK Adult ADHD Network and criminal justice agencies. BMC Psychiatry 2011; 11:32.
40. Wigal TE, Brams M,Gasior M, etal. Effect size of lisd exam fetam in edimesylate in adults with attention-deficit/hyperactivity disorder. Postgrad Med 2011; 123:169-176.
41. Adler LA, Libowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009; 26:212-221.
42. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011; 306: 2673-2683.
43. Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry 2012; 169:178-185.
44. Van Emmerik-van Oortmersesen K, van de Glind G, van den Brink W, et al. Prevalence of attention-deficit/hyperactivity disorder in substance use disorder patients: a meta-analysis and a meta-regression analysis. Drug Alcohol Depend 2012; 122:11-19.
45. Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/ hyper-activity disorder and future substance use disorder: comparative meta-ana-lyses. J Am Acad Child Adolesc Psychiatry 2011; 50:9-21.
46. Wigal TE, Morrison NR. The intersection of attention-deficit/ hyperactivity disorder and substance abuse. Curr Opin Psychiatry 2011; 24:280-285.
47. Geller D, Donelli C, Lopez F, etal.Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:1119-1127. (Pubitemid 47295923)
48. Gibson AP, Bettinger TL, Patel NC, Crismon ML Atomoxetine versus stimulants for treatment of attention deficit hyperactivity disorder in children and adolescents. Ann Pharmacother 2006; 40:1134-1142. (Pubitemid 43886972)
49. Covey LS, Hu MC, Weissman J, et al. Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate. Nicotine Tob Res 2011; 13:1003-1008.